Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma

Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there are no clinical agents available to effectively tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-Uribe, Patricia, Adrianzen-Ruesta, Maria Paz, Deng, Zhong, Echevarria-Vargas, Ileabett, Mender, Ilgen, Saheb, Steven, Liu, Qin, Altieri, Dario C., Murphy, Maureen E., Shay, Jerry W., Lieberman, Paul M., Villanueva, Jessie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062502/
https://www.ncbi.nlm.nih.gov/pubmed/29695835
http://dx.doi.org/10.1038/s41388-018-0247-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062502/
https://www.ncbi.nlm.nih.gov/pubmed/29695835
http://dx.doi.org/10.1038/s41388-018-0247-7

Ejemplares similares